- Home
- LNKB vs CLLS Comparison
LNKB vs CLLS Comparison
Compare LNKB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | CLLS |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.5M | 384.3M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LNKB | CLLS |
|---|---|---|
| Price | $8.95 | $4.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 85.9K | 33.9K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 26.76 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $186,504,000.00 | N/A |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $9.33 | $0.62 |
| P/E Ratio | $9.92 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $6.44 | $1.33 |
| 52 Week High | $9.59 | $5.48 |
Technical Indicators
Market Signals| Indicator | LNKB | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.06 | 60.47 |
| Support Level | $7.01 | $3.25 |
| Resistance Level | $9.02 | $4.48 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 86.50 | 75.33 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.